Advertisement

Volume 132, Issue 1

 

 

July 5, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: A new β2 integrin ligand in inflamed tissue.
See the article by Yakubenko et al.

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
The treatment combination of brentuximab with bendamustine for refractory or relapsing classical Hodgkin’s lymphoma produces high and durable rates of progression-free survival at 20 months of follow-up, a practice-changing result.


Oxidative modifications of extracellular matrix promote the second wave of inflammation via β2 integrins
Yakubenko et al report an important role for carboxyethylpyrrole, a lipid oxidation product generated by extravasated neutrophils within inflamed tissue, in guiding infiltrating macrophages during the second wave of immune cell invasion via β2 integrins.


Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis
The genetic findings in a large cohort of children with hemophagocytic lymphohistiocytosis (HLH) indicate that pediatric HLH in many cases may be explained by mutations in genes other than those required for lymphocyte cytotoxicity.


Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease
This article offers a unique genomic and phenotypic catalogue of hepcidin-deficient hemochromatosis.


Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?
This Blood Spotlight on the differential pathogenesis of Epstein-Barr virus (EBV)–related and EBV-unrelated Hodgkin lymphoma (HL) is of particular relevance in light of the therapeutic advances in relapsed/refractory HL that have recently emerged through the use of checkpoint inhibitors.


Novel therapeutics for hemophilia and other bleeding disorders
The field of therapeutics for hemophilia finds itself in a state of flux. This concise review highlights emerging new therapies for hemophilia, von Willebrand disease, and other congenital bleeding disorders.


How and when I do allogeneic transplant in CLL
In a comprehensive How I Treat article, John G. Gribben discusses the approach and rationale for using allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia (CLL) in the face of many new therapeutic agents for this disease.


A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
This study confirms the prognostic validity of the follicular lymphoma international prognostic index in the era of immunochemotherapy and presents a simpler index with a similar discriminative ability.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.